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1. INTRODUCTION {#epi412339-sec-0001}
===============

Epilepsy with myoclonic absences (EMA) is a rare epilepsy syndrome clinically characterized by absences accompanied by marked, diffuse, rhythmical myoclonias and often associated with a progressive tonic contraction.[1](#epi412339-bib-0001){ref-type="ref"} This seizure type is categorized as a generalized onset and nonmotor seizure and accompanied by various degrees of neurodevelopmental disorders (NDDs). Genetic etiologies of EMA remain to be largely elucidated. Previous whole‐exome sequencing (WES) studies described some epilepsy genes, including *SYNGAP1*,[2](#epi412339-bib-0002){ref-type="ref"} *GLUD1*,[3](#epi412339-bib-0003){ref-type="ref"} *SCN1A*,[4](#epi412339-bib-0004){ref-type="ref"} and *SLC2A1*,[5](#epi412339-bib-0005){ref-type="ref"} as having a possible association with EMA.

*SETD1B* (SET domain containing 1B) encodes a histone H3 lysine 4 (H3K4) methyltransferase, which is involved in the epigenetic control of the chromatin structure and gene expression.[6](#epi412339-bib-0006){ref-type="ref"} De novo microdeletions in the 12q24.3 region encompassing *SETD1B* were associated with syndromic NDDs,[7](#epi412339-bib-0007){ref-type="ref"} and two de novo variants in *SETD1B* have been reported in developmental disorders in a large cohort exome study.[8](#epi412339-bib-0008){ref-type="ref"} Recently, we reported two individuals with de novo *SETD1B* variants who had epilepsy (one showed EMA), developmental delay, intellectual disabilities (ID), autistic behavior, and craniofacial dysmorphic features.[9](#epi412339-bib-0009){ref-type="ref"} These findings suggested that de novo *SETD1B* variants are causative for NDDs with epilepsy.

Here, we report a new individual with a de novo *SETD1B* missense variant having EMA, ID, language disorder, and autism spectrum disorder (ASD). We will discuss the phenotypic features of *SETD1B*‐associated disorders.

2. METHODS {#epi412339-sec-0002}
==========

After receiving written informed consent, the genomic DNA of the patient and his parents was extracted from blood leukocytes. Genomic DNA of the patient was captured using a SureSelect Human All Exon V6 kit (Agilent Technologies) and sequenced by a NextSeq 500 (Illumina) with 150‐bp paired‐end reads. Exome data processing, variant calling, and variant annotation were performed as previously described.[9](#epi412339-bib-0009){ref-type="ref"} Candidate variants were confirmed by Sanger sequencing. Biological parentage was confirmed by analyzing 10 microsatellite markers. Experimental protocols were approved by the Institutional Review Board of Hamamatsu University School of Medicine.

3. RESULTS {#epi412339-sec-0003}
==========

3.1. Case presentation {#epi412339-sec-0004}
----------------------

A Japanese boy was born to nonconsanguineous healthy parents as a second child without asphyxia at 37 weeks of gestation. His birthweight and length were 3,008 g (+0.82 standard deviation \[SD\]) and 50 cm (+1.4 SD), respectively. There was no family history of NDDs. He required respirator support because of transient tachypnea of the newborn. Although his motor development was normal, his language development was markedly delayed. He spoked his first word at 2 years and 3 months old and was able to combine two words at 3 years old. At 5 years old, he was diagnosed with mild ID (intelligence quotient \[IQ\] 64, Tanaka‐Binet Intelligence Scale). At 6 years old, his full‐scale IQ (WISC‐IV) was 56. He poorly interacted with others and showed hyperactive behavior. He was then diagnosed as ASD at 6 years old based on the Pervasive Developmental Disorders Autism Society Japan Rating Scale.[10](#epi412339-bib-0010){ref-type="ref"}

At 3 years and 7 months old, he began to show myoclonic absence seizures lasting 3‐5 seconds and occurring 4‐5 times per day. His seizures were refractory to antiepileptic drugs including valproate, ethosuximide, levetiracetam, clobazam, and topiramate. The ketogenic diet was also tried but interrupted because he did not appreciate the importance of the treatment. At 7 years and 10 months old, interictal electroencephalogram (EEG) revealed a spike‐and‐slow wave complex with dominance in the frontal area (Figure [1](#epi412339-fig-0001){ref-type="fig"}). In an ictal video‐EEG and polygraph (EEG and electromyogram) recording, diffuse synchronous 3‐Hz spike‐and‐wave bursts were observed synchronized with bilateral upper limb myoclonic jerks accompanied by loss of consciousness. These findings matched the criteria of myoclonic absence seizure. At the time of this writing, his myoclonic absence seizures occur 10‐20 times per day and last 30 seconds despite valproate and lamotrigine treatment.

![EEG findings and the *SETD1B* variant in the patient. A, Interictal EEG at 7 years old. EEG showed frontally dominant generalized spike‐and‐wave discharges. B, Ictal EEG at 7 years old. EEG revealed 3‐Hz diffuse spike‐and‐wave discharges with myoclonic jerks rhythmically repeated at 3 Hz. Electromyography (EMG) recorded on the left trapezius muscle. C, Familial pedigrees and *SETD1B* variants. Sanger sequencing showed a de novo variant in *SETD1B*. +, wild‐type allele. D, Schematic presentation of the SETD1B protein. The variants identified in our study are depicted below, and the variants in previous large cohort studies[20](#epi412339-bib-0020){ref-type="ref"}, [21](#epi412339-bib-0021){ref-type="ref"}, [22](#epi412339-bib-0022){ref-type="ref"} are shown above. Variants are represented with black triangles (missense) or a red diamond (frameshift). Locations of variants are annotated based on a new NCBI Reference Sequence: [NM_001353345.1](NM_001353345.1) (released on December 25, 2018). Multiple amino acid sequences of SETD1B were aligned using the ClustalW tool](EPI4-4-476-g001){#epi412339-fig-0001}

Upon final examination at 8 years and 1 month old, his height was 124.6 cm (−0.23 SD), his weight was 28.8 kg (+0.49 SD), and his head circumference was 54.5 cm (+1.4 SD). He had no dysmorphic features. Brain MRI showed normal brain structure.

3.2. Variant screening {#epi412339-sec-0005}
----------------------

Using WES, we searched for candidate variants in known epilepsy‐ and NDD‐related genes and found a possible pathogenic variant in *SETD1B* ([NM_001353345.1](NM_001353345.1): c.386T\>G, p.(Val129Gly)). Sanger sequencing confirmed that this variant occurred de novo (Figure [1](#epi412339-fig-0001){ref-type="fig"}C). It was absent in our 218 in‐house Japanese control exomes and public databases including the gnomAD (<http://gnomad.broadinstitute.org/>) and 2KJPN (<https://ijgvd.megabank.tohoku.ac.jp/>). This variant was predicted to be deleterious by multiple in silico pathogenicity prediction tools: The CADD PHRED score was 28.3 (<http://cadd.gs.washington.edu/snv>), the PP2_HVAR score was 0.994 (<http://genetics.bwh.harvard.edu/pph2/>), the SIFT score was 0 (<http://sift.jcvi.org/>), the MutationTaster score was 1.0 (<http://www.mutationtaster.org/>), and the Missense Tolerance Ratio was 0.503 (24.9th percentile \<25th percentile; <http://mtr-viewer.mdhs.unimelb.edu.au/mtr-viewer/>).[11](#epi412339-bib-0011){ref-type="ref"} The variant was considered likely pathogenic according to ACMG Standards and Guidelines (PS2, PM2, PP3). The altered residue was located at the RNA recognition motif (RRM) domain and highly evolutionarily conserved (Figure [1](#epi412339-fig-0001){ref-type="fig"}D). We also examined possible pathogenic copy number variants (CNVs) using WES data with the eXome‐Hidden Markov Model (XHMM)[12](#epi412339-bib-0012){ref-type="ref"} and the methods developed by Nord et al[13](#epi412339-bib-0013){ref-type="ref"}; however, no possible pathogenic CNVs were found in this case. These findings suggested that this variant is likely to be pathogenic in this case.

4. DISCUSSION {#epi412339-sec-0006}
=============

To date, we found three de novo *SETD1B* variants in three unrelated Japanese individuals with NDDs and epilepsy. The clinical manifestations of these individuals are summarized in Table [1](#epi412339-tbl-0001){ref-type="table"}. In all cases, the developmental milestones were delayed before the onset of seizures. They started to show autistic behaviors and various degrees of ID in early childhood. However, facial dysmorphic features were seen in only one of the three individuals. Epilepsy is also common to all the three individuals. Individuals with microdeletion of 12q24.31 including *SETD1B* also had epilepsy in two of the four cases,[8](#epi412339-bib-0008){ref-type="ref"} suggesting that epilepsy is strongly associated with *SETD1B* defects, although clinical features could be modified by defects in other genes located within the deletion interval. Interestingly, EMA was noted in two of the three individuals.[9](#epi412339-bib-0009){ref-type="ref"}, [14](#epi412339-bib-0014){ref-type="ref"} EMA is a rare and specific type of seizure that was accounts for 0.5%‐1% of total epilepsies.[1](#epi412339-bib-0001){ref-type="ref"} Although the myoclonic seizures of the remaining case were not thought to be myoclonic absences based on interictal EEG findings, evidence suggests that *SETD1B* may be a candidate gene for EMA.

###### 

Clinical features of cases of de novo SETD1B variants

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Individuals                       This patient                                        Previously reported cases[9](#epi412339-bib-0009){ref-type="ref"}, [14](#epi412339-bib-0014){ref-type="ref"}   
  --------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  *SETD1B* variants                 c.386T\>G                                           c.5653C\>T                                                                                                     c.5704C\>T

  p.(Val129Gly)                     p.(Arg1885Trp)                                      p.(Arg1902Cys)                                                                                                 

  Sex, age                          Male, 7 y                                           Female, 12 y                                                                                                   Male, 34 y

  Seizure onset                     3 y and 7 mo                                        2 y and 9 mo                                                                                                   3 y and 11 mo

  Seizure type at onset             Myoclonic absence seizure                           Myoclonic seizures                                                                                             Myoclonic seizures

  Myoclonic absence seizure onset   3 y and 7 mo                                        2 y and 10 mo                                                                                                  NA

  Course of seizures                Myoclonic absence seizure                           Myoclonic absence seizure                                                                                      Generalized tonic seizures

  Initial interictal EEG            Spike‐and‐slow wave complex dominant frontal area   2‐ to 3‐Hz diffuse spike‐and‐wave bursts with slow wave dominant background                                    3‐ to 4‐Hz frontally dominant\
                                                                                                                                                                                                       spike‐and‐slow wave complexes or polyspike‐and‐slow wave complexes

  Ictal EEG                         3‐Hz diffuse spike‐and‐wave burst                   Generalized spike‐and‐waves of 3‐4 Hz, with an anterior predominance                                           NA

  Course of interictal EEG          Spike‐and‐slow wave complex dominant frontal area   No epileptiform discharge with rhythmic theta wave                                                             Focal spike‐and‐slow wave complex

  Response to treatment             Daily seizure with VPA and LTG                      Seizure‐free from 6 ywith LTG                                                                                  Monthly seizure with VPA, CBZ and TPM

  Dysmorphic features               −                                                   −                                                                                                              \+

  Intellectual disability           Mild                                                Mild                                                                                                           Profound

  IQ                                56 (WISC‐IV)                                        64 (TK‐Binet)                                                                                                  10 (TK‐Binet)

  Autism/autistic behavior          \+                                                  \+                                                                                                             \+

  Anxiety                           \+                                                  −                                                                                                              \+

  Language delay                    \+                                                  \+                                                                                                             \+

  Motor development                 Normal                                              Walk without support                                                                                           Walk without support

  Brain image                       Normal                                              Normal                                                                                                         Normal

  Cancer                            NA                                                  NA                                                                                                             Sigmoid cancer
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CBZ, carbamazepine; LTG, lamotrigine; NA, not assessed or not available; TPM, topiramate; VPA, valproate.
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Previous work suggested that histone H3 lysine 4 trimethylation (H3K4me3) was involved in learning and memory consolidation.[15](#epi412339-bib-0015){ref-type="ref"} Animal models showed that the level of H3K4me3 increased in the CA1 region of the dorsal hippocampus during memory retrieval.[16](#epi412339-bib-0016){ref-type="ref"} Moreover, it was revealed that the variants in genes constituting components of the H3K4 regulatory machinery caused rare congenital dysmorphic syndromes with NDDs involving ID, ASD, and schizophrenia.[17](#epi412339-bib-0017){ref-type="ref"} These findings indicated that the dysfunction of the enzymatic activity of SETD1B may be likely to reduce H3K4me3 in the neuronal system and cause disabilities of normal learning and consolidation of memories. Meanwhile, involvement of epilepsy was variable in cases with variants in histone H3K4 methyltransferases. Our data suggest that epilepsy is strongly associated with *SETD1B* defects. In regulating the H3K4 trimethylation pattern in mammalian cells, WDR82 is a component of the SETD1A and SETD1B complexes that influence target selection, but is not associated with other SET1‐family complexes such as KMT2A‐KMT2D.[18](#epi412339-bib-0018){ref-type="ref"} In addition, it has been reported that SETD1B has more robust trimethylase activities than KMT2A‐KMT2D.[18](#epi412339-bib-0018){ref-type="ref"} Therefore, it might be possible that a strong defect of trimethylase activity caused by *SETD1B* defects is closely associated with the epilepsy phenotype.

SETD1B belongs to the SET1 family of histone H3K4 methyltransferases. It is an important component of the histone methyltransferase complex that generates mono‐, di‐, and trimethylated histone H3 at Lys4 and has been implicated in multiple biological processes.[6](#epi412339-bib-0006){ref-type="ref"} SETD1B has four evolutionarily conserved functional domains: the RRM domain, the N‐SET domain, the catalytic SET domain, and the post‐SET domain. The SET domain plays a principal role in catalyzing histone methylation, and loss‐of‐function variants in this domain may cause impairment of enzymatic activity of H3K4 methyltransferase. The RRM domain is commonly shared by the many RNA binding proteins used for interaction with RNA bases. It acts as a positive regulator of trimethylation by SET1‐family methyltransferases, and dysfunction in the RRM domain may bring about inadequate trimethylation leading to an abnormal transcriptional regulation of genes.[19](#epi412339-bib-0019){ref-type="ref"} Therefore, loss‐of‐function variants in the RRM domain may also induce dysregulation of enzymatic activity of H3K4 methyltransferase. In previous and present studies, eight de novo variants in *SETD1B* had been identified in individuals with neurodevelopmental or psychiatric diseases[20](#epi412339-bib-0020){ref-type="ref"}, [21](#epi412339-bib-0021){ref-type="ref"}, [22](#epi412339-bib-0022){ref-type="ref"} (Table [S1](#epi412339-sup-0001){ref-type="supplementary-material"}). Four missense *SETD1B* variants were located in the SET domain or RRM domain, and these four variants were predicted to be deleterious by multiple in silico tools. While the p.(Thr1005Asnfs\*4) is a null variant and is very likely to be pathogenic, the pathogenicity of the other missense variants located outside the domain was less significant (Table [S1](#epi412339-sup-0001){ref-type="supplementary-material"}). All three patients in our work showed very similar phenotypes although their variants were located in the different domains. The clinical details of the previous studies were not available, but both missense and protein‐truncating variants may cause developmental disorders. Therefore, loss‐of‐function variants in the functional domains of SETD1B may induce dysregulation of enzymatic activity of H3K4 methyltransferase and have association with the etiology of neurodevelopmental disorders. However, further accumulation of additional cases will need to clarify the pathogenicity of variants and phenotype‐genotype correlations.

In conclusion, we described an additional case of a de novo *SETD1B* variant with EMA, developmental delay, ID, and ASD. This case supports the indication that *SETD1B* may be a causative gene for syndromic NDD with epilepsy, especially its association with EMA. However, further accumulation of cases and functional analyses are necessary for clarifying the phenotypic spectrum and the pathogenesis of *SETD1B*‐related disorders.
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